Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up ...

Novo Nordisk launched its latest campaign – My Ozempic ... said the team was initially inspired to create the campaign when the FDA expanded Ozempic’s indication to treat chronic kidney disease for ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

U.S.-listed shares of Novo Nordisk, which produces obesity drugs Ozempic and Wegovy ... dysfunction-associated fatty liver disease, and chronic kidney diseases. It has been approved for U.S ...

Singer Michael Trotter Jr of The War and Treaty, chef Franklin Becker of “Top Chef Masters,” and a beauty salon owner ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

PLAINSBORO, N.J., March 3, 2025 /PRNewswire/ -- Novo Nordisk launched "My Ozempic ® Era" today, a national campaign which spotlights the longstanding Ozempic ® patient community by sharing ...

Those who live with type 2 diabetes have an increased risk of developing chronic kidney disease and are more ... of U.S. Diabetes Therapeutic Area at Novo Nordisk. "By spotlighting the real ...